Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients

Oncology Reports

Volumn 14, Issue 4, 2005, Pages 1029-1036

  Solassol, Isabelle ^a   Caumette, Laetitia ^a   Bressolle, Françoise ^a,b   Garcia, Frédéric ^a   Thézenas, Simon ^a   Astre, Cécile ^a   Culine, Stéphane ^a   Coulouma, Rémi ^a   Pinguet, Frédéric ^a  

^a Department of Oncopharmacology   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Bioavailability; Cancer pain; Fentanyl; Intra and interindividual variability; Transdermal therapeutic system

Indexed keywords

FENTANYL; NARCOTIC ANALGESIC AGENT;

AGED; ARTICLE; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; KINETICS; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; NEOPLASM; PAIN; PALLIATIVE THERAPY; REPRODUCIBILITY; TIME;

ADMINISTRATION, CUTANEOUS; AGED; ANALGESICS, OPIOID; DRUG DELIVERY SYSTEMS; FEMALE; FENTANYL; HUMANS; KINETICS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PAIN; PALLIATIVE CARE; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 33644825166     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.4.1029     Document Type: Article

References (24)

1. Portenoy RK: Cancer pain: pathophysiology and syndromes. Lancet 339: 1026-1031, 1992.
2. Levy MH: Pharmacologic treatment of cancer pain. New Engl J Med 335: 1124-1132, 1996.
3. Payne R, Chandler S and Einshaus M: Guidelines for clinical use of transdermal fentanyl. Anticancer Drugs 6 (suppl 3): 50-53, 1995.
4. Muijsers RB and Wagstaff AJ: Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 61: 2289-2307, 2001. (Pubitemid 34074808)
5. Tawfik MO, Bryuzgin V and Kourteva G: Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin 20: 259-267, 2004. (Pubitemid 38339167)
6. Jeal W and Benfield P: Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 53: 109-138, 1997. (Pubitemid 27042235)
7. Zambaux MF, Bonneaux F, Du HP and Labrude P: Validation of a method to inactivate fentanyl in the used devices of Durogésic®. Ann Pharm Fr 58: 176-179, 2000. (Pubitemid 30326381)
8. Marquardt KA, Tharratt RS and Musallam NA: Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother 29: 969-971, 1995.
9. Gupta SK, Southam M, Gale R and Hwang SS: System functionality and physicochemical model of fentanyl transdermal system. J Pain Symptom Manage 7 (suppl 3): S17-S26, 1992.
10. Gardner-Nix J: Caregiver toxicity from transdermal fentanyl. J Pain Symptom Manage 21: 447-448, 2001.
11. Levron JC, Le Moing JP, Chauvin M, Duvaldestin P, Camboulives J and Ferrier C: Pharmacocinétique du fentanyl par voie percutanée: influence de l'âge. In: Pharmacocinétique de la recherche å la clinique. Brès J and Panis G (eds). J Pharm Clin, John Libbey Eurotext, Paris, pp199-203, 1992.
12. Esteve M, Levron JC, Flaisler B, Schoefler P, Duvaldestin P and Chauvin M: Does aging modify pharmacokinetics of transdermal fentanyl? Anesthesiology 75: 705, 1991.
13. Holdsworth MT, Forman WB, Killilea TA, Nystrom KM, Paul R, Brand SC and Reynolds R: Transdermal fentanyl disposition in elderly subjects. Gerontology 40: 32-37, 1994. (Pubitemid 24108091)
14. Rung GW and Riemondy S: The effect of skin temperature on transdermal fentanyl therapy. Anesth Analg 76: 363, 1993.
15. Donner B, Zenz M, Strumpf M and Raber M: Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 15: 168-175, 1998. (Pubitemid 28169139)
16. Shomaker TS, Zhang J and Ashburn MA: Assessing the impact of heat on the systemic delivery of fentanyl through the transdermal fentanyl delivery system. Pain Med 1: 225-230, 2000.
17. Calis KA: Transdermally administered fentanyl for pain management. Clin Pharm 11: 22-36, 1992.
18. Sebel PS: Transdermal absorption of fentanyl and sufentanil in man. Eur J Clin Pharmacol 32: 529-531, 1987.
19. Southam M, Gupta S, Knowles M and Hwang SS: An overview of pharmacokinetics, efficacy and safety. In: Transdermal fentanyl. Lehmann KA and Zech D (eds). Springer, New York, NY, pp107-116, 1991.
20. Foley PL, Henderson AL, Bissonette EA, Wimer GR and Feldman SH: Evaluation of fentanyl transdermal patches in rabbits: blood concentrations and physiologic response. Comp Med 51: 239-244, 2001. (Pubitemid 32661988)
21. Varvel JR, Shafer SL, Hwang SS, Coen PA and Stanski DR: Absorption characteristics of transdermally administered fentanyl. Anesthesiology 70: 928-934, 1989. (Pubitemid 19148495)
22. Portenoy RK, Southam MA, Gupta SK, et al: Transdermal fentanyl for cancer pain: repeated dose pharmacokinetics. Anesthesiology 78: 36-43, 1993. (Pubitemid 23038976)
23. Nugent M, Davis C, Brooks D and Ahmedzai SH: Long-term observations of patients receiving transdermal fentanyl after a randomized trial. J Pain Symptom Manage 21: 385-391, 2001. (Pubitemid 32452138)
24. Roy SD and Flynn GL: Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. Pharm Res 7: 842-847, 1990. (Pubitemid 20332536)